Novel clearance mechanisms of platelets

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 585-589

  Grozovsky, Renata ^a   Hoffmeister, Karin M ^a   Falet, Hervé ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

glycans; immune thrombocytopenia; lectins; platelet clearance; Wiskott Aldrich syndrome

Indexed keywords

ALPHAMBETA2 INTEGRIN; ASHWELL MORELL RECEPTOR; CELL RECEPTOR; FIBRINOGEN RECEPTOR; GLYCAN; INTEGRIN; LECTIN; SIALIC ACID; SIALYLTRANSFERASE; THROMBIN RECEPTOR; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG; WISKOTT ALDRICH SYNDROME PROTEIN;

AUTOIMMUNE THROMBOCYTOPENIA; CELL METABOLISM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INDUCED HYPOTHERMIA; KUPFFER CELL; LIVER CELL; LIVER CLEARANCE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOCYTE; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; WISKOTT ALDRICH SYNDROME;

ANIMALS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; MICE; PLATELET COUNT; PLATELET TRANSFUSION; THROMBOCYTOPENIA; WISKOTT-ALDRICH SYNDROME;

EID: 78049276308     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833e7561     Document Type: Review

References (47)

1. Murphy S, Rebulla P, Bertolini F, et al. In vitro assessment of the quality of stored platelet concentrates. The BEST (Biomedical Excellence for Safer Transfusion) Task Force of the International Society of Blood Transfusion. Transfus Med Rev 1994; 8:29-36.
2. Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99:4-13.
3. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 2007; 44:S3-S11.
4. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113:6511-6521.
5. Kuhne T, Buchanan GR, Zimmerman S, et al. Intercontinental Childhood ITPSG: a prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003; 143:605-608.
6. Imbach P, Kuhne T, Muller D, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006; 46:351-356.
7. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4:2377-2383.
8. Chan H, Moore JC, Finch CN, et al. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2003; 122:818-824.
9. Crow AR, Lazarus AH. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25 (Suppl 1):S14-S18.
10. Sandler SG. The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. Semin Hematol 2000; 37:10-12.
11. Kuhne T, Blanchette V, Buchanan GR, et al. Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 2007; 49:829-834.
12. Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33-40.
13. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008; 112:1147-1150.
14. AuBuchon JP, Herschel L, Roger J, Murphy S. Preliminary validation of a new standard of efficacy for stored platelets. Transfusion 2004; 44:36-41.
15. Rumjantseva V, Hoffmeister KM. Novel and unexpected clearance mechanisms for cold platelets. Transfus Apher Sci 2009; 42:63-70.
16. Hoffmeister K, Felbinger T, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell 2003; 10:87-97.
17. Hoffmeister K, Josefsson E, Isaac N, et al. Glycosylation restores survival of chilled blood platelets. Science 2003; 301:1531-1534.
18. QC-stored platelets. Blood 2008; 111:3249-3256.
19. Valeri C, Giorgio A, Macgregor H, Ragno G. Circulation and distribution of autotransfused fresh, liquid-preserved and cryopreserved baboon platelets. Vox Sang 2002; 83:347-351.
20. Rumjantseva V, Grewal PK, Wandall HH, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009; 15:1273-1280.
21. Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008; 14:648-655.
22. Ellies L, Ditto D, Levy G, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA 2002; 99:10042-10047.
23. Sørensen AL, Rumjantseva V, Nayeb-Hashemi S, et al. Role of sialic acid for platelet life span: exposure of b-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 2009; 114:1645-1654.
24. Steiner M, Vancura S. Asymmetrical loss of sialic acid from membrane glycoproteins during platelet aging. Thromb Res 1985; 40:465-471.
25. Greenberg J, Packham M, Cazenave J, et al. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 1975; 32:476-484.
26. Bratosin D, Mazurier J, Debray H, et al. Flow cytofluorimetric analysis of young and senescent human erythrocytes probed with lectins: evidence that sialic acids control their life span. Glycoconj J 1995; 12:258-267.
27. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117:725-738; quiz 739.
28. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115:3231-3238.
29. Gross BS, Wilde JI, Quek L, et al. Regulation and function of WASp in platelets by the collagen receptor, glycoprotein VI. Blood 1999; 94:4166-4176.
30. Falet H, Hoffmeister KM, Neujahr R, Hartwig JH. Normal Arp2/3 complex activation in platelets lacking WASp. Blood 2002; 100:2113-2122.
31. Haddad E, Cramer E, Riviere C, et al. The thrombocytopenia of Wiskott-Aldrich syndrome is not related to a defect in proplatelet formation. Blood 1999; 94:509-518.
32. Sabri S, Foudi A, Boukour S, et al. Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 2006; 108:134-140.
33. Grottum KA, Hovig T, Holmsen H, et al. Wiskott-Aldrich syndrome: qualitative platelet defects and short platelet survival. Br J Haematol 1969; 17:373-388.
34. Murphy S, Oski FA, Naiman JL, et al. Platelet size and kinetics in hereditary and acquired thrombocytopenia. N Engl J Med 1972; 286:499-504.
35. Prislovsky A, Marathe B, Hosni A, et al. Rapid platelet turnover in WASP(\-) mice correlates with increased ex vivo phagocytosis of opsonized WASP(\-) platelets. Exp Hematol 2008; 36:609-623.
36. Falet H, Marchetti MP, Hoffmeister KM, et al. Platelet-associated IgAs and impaired GPVI responses in platelets lacking WIP. Blood 2009; 114:4729-4737.
37. Curcio C, Pannellini T, Lanzardo S, et al. WIP null mice display a progressive immunological disorder that resembles Wiskott-Aldrich syndrome. J Pathol 2007; 211:67-75.
38. Corash L, Shafer B, Blaese RM. Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndrome. Blood 1985; 65:1439-1443.
39. Semple JW, Siminovitch KA, Mody M, et al. Flow cytometric analysis of platelets from children with the Wiskott-Aldrich syndrome reveals defects in platelet development, activation and structure. Br J Haematol 1997; 97:747-754.
40. DeSanto NG, Sessa A, Capodicasa G, et al. IgA glomerulonephritis in Wiskott-Aldrich syndrome. Child Nephrol Urol 1988; 9:118-120.
41. Matsukura H, Kanegane H, Miya K, et al. IgA nephropathy associated with X-linked thrombocytopenia. Am J Kidney Dis 2004; 43:e7-e12.
42. Parkman R, Remold-O'Donnell E, Kenney DM, et al. Surface protein abnormalities in lymphocytes and platelets from patients with Wiskott-Aldrich syndrome. Lancet 1981; 2:1387-1389.
43. Remold-O'Donnell E, Kenney DM, Parkman R, et al. Characterization of a human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome. J Exp Med 1984; 159:1705-1723.
44. Greer WL, Higgins E, Sutherland DR, et al. Altered expression of leucocyte sialoglycoprotein in Wiskott-Aldrich syndrome is associated with a specific defect in O-glycosylation. Biochem Cell Biol 1989; 67:503-509.
45. Higgins EA, Siminovitch KA, Zhuang DL, et al. Aberrant O-linked oligosaccharide biosynthesis in lymphocytes and platelets from patients with the Wiskott-Aldrich syndrome. J Biol Chem 1991; 266:6280-6290.
46. Piller F, Le Deist F, Weinberg KI, et al. Altered O-glycan synthesis in lymphocytes from patients with Wiskott-Aldrich syndrome. J Exp Med 1991; 173:1501-1510.
47. HaraT, Yamauchi M,Takahashi E, et al. The UDP-galactose translocator gene is mapped to band Xp11.23-p11.22 containing the Wiskott-Aldrich syndrome locus. Somat Cell Mol Genet 1993; 19:571-575.